PURPOSE Studies | PURPOSE 365 Study

Actor portrayal.

Welcome to PURPOSE 365

What if once-yearly HIV prevention was possible?

Today, PrEP (pre-exposure prophylaxis) is only available as a daily pill or an injection every few months. These options may be challenging for some people to keep up with. PURPOSE 365 is a clinical trial that is focused on testing an investigational PrEP medication, lenacapavir, which could transform HIV prevention with its once-yearly intramuscular injection schedule. This longer-acting, injectable PrEP option could be more desirable for certain individuals, and ultimately make it easier for them to stick to their HIV PrEP routine. It could also make PrEP a more realistic option for more people who may want or need it.

PURPOSE 365 is taking place in the United States and is currently enrolling participants.

Do you qualify?

Actor portrayal.

“How Is This Related to Me?”

Currently, the available PrEP options may not work for everyone who wants or needs them. This can make it hard for people to start or keep taking PrEP.

Answer 4 quick questions below to find out if you’re eligible to participate in PURPOSE 365.

PURPOSE 365 is evaluating an investigational PrEP medication, lenacapavir, administered once a year, which has the potential to provide an additional option to people who want or need PrEP.

Enrolling in this HIV PrEP study gives you a unique opportunity to contribute to the development of a potentially life-changing treatment for HIV prevention. Your participation could lead to the availability of a more manageable, long-acting treatment option, possibly overcoming many of the existing barriers current HIV PrEP options have.

Find out more about PURPOSE 365 to see if you could be a part of advancing HIV prevention and changing medical research for the better.

Do you qualify?

Our Commitment to Inclusion

From day 1, Gilead designed the PURPOSE 365 study with all people who would benefit from PrEP in mind.

Explore a video from Moupali Das, MD, MPH, the Executive Director of HIV Clinical Development at Gilead, as she describes why it was important that PURPOSE add study sites in new locations across the country.

Global Community Advisors

Actor portrayal.

PURPOSE 365 Questionnaire

Thank you for your interest in participating in the
PURPOSE 365 study.

Answer these 4 questions to see if you may be eligible to take part in the study:

Yes No

Are you 16 or older?

Have you been sexually active with a partner assigned male at birth in the past 6 months?

Have you received oral lenacapavir in the past 90 days or injectable lenacapavir in the previous 18 months (1.5 years)?

Have you ever tested positive for HIV?

Your privacy matters to us. Note that your answers will only be used to let you know whether or not you qualify, and will not be stored or tracked in any way.

Welcome to PURPOSE 365

“How Is This Related to Me?”

Our Commitment to Inclusion

From day 1, Gilead designed the PURPOSE 365 study with all people who would benefit from PrEP in mind.

PURPOSE 365 Questionnaire

You may not qualify, but there are still ways you can help!

You may qualify!